Analyst Ratings for Mirum Pharmaceuticals MIRM last quarter range from bullish to bearish, as provided by 4 analysts.
The table below provides a concise overview of recent analyst ratings, offering insights into changes in sentiment over the past 30 days and drawing comparisons to previous months for a holistic perspective.
| Bullish | A little bullish | Indifferent | A little bearish | Bearish | |
|---|---|---|---|---|---|
| Total ratings | 2 | 2 | 0 | 0 | 0 |
| Last 30 days | 0 | 1 | 0 | 0 | 0 |
| 1 million ago | 0 | 0 | 0 | 0 | 0 |
| 2 million ago | 0 | 1 | 0 | 0 | 0 |
| 3 million ago | 2 | 0 | 0 | 0 | 0 |
The 12-month price targets rated by analysts reveal further insights, with an average target of $55.25, a high estimate of $64.00 and a low estimate of $35.00. This current average represents a decrease of 19.93% from the previous average price target of $69.00.
Analyst Ratings Analysis: A Detailed Analysis
A comprehensive examination of how financial experts perceive Mirum Pharmaceuticals comes from recent analyst actions. Below is a detailed summary of the top analysts, their recent ratings, and adjustments to ratings and price targets.
| Analyst | Analytics company | Action taken | Assessment | Current price target | Previous price target |
|---|---|---|---|---|---|
| Josh Shimmer | Singer Fitzgerald | Maintains | Overweight | $35.00 | – |
| Jonathan Wolleben | JMP Titles | Maintains | Market outperformance | $64.00 | – |
| Steven Seedhouse | Raymond James | Lower | Strong buy | $64.00 | $78.00 |
| And Arce | H. C. Wainwright & Co. | Lower | Acquire | $58.00 | $60.00 |
Key Insights:
- Action taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they “maintain,” “raise” or “lower” their position reflects their reaction to recent developments related to Mirum Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.
- Assessment: Drilling down into the ratings, analysts assign qualitative values, from “Outperform” to “Underperform”. These ratings communicate expectations for Mirum Pharmaceuticals’ relative performance compared to the broader market.
- Price targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Mirum Pharmaceuticals stock. This examination reveals changes in analyst expectations over time.
Gain valuable insights into Mirum Pharmaceuticals’ market position by understanding these analyst ratings along with relevant financial indicators. Stay informed and make strategic decisions with our ratings table.
Stay updated on the ratings of Mirum Pharmaceuticals analysts.
If you’re interested in following the news and performance of small-cap stocks, you can start by tracking them here.
Insight into the background of Mirum Pharmaceuticals
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel orally administered ileal bile acid transporter “IBAT” inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). He is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver disease.
Analyzing the financial performance of Mirum Pharmaceuticals
Market capitalization analysis: With a deep presence, the company’s market capitalization is higher than industry averages. This reflects the considerable size and strong recognition of the market.
Revenue growth: Mirum Pharmaceuticals’ revenue growth over a 3-month period has been noteworthy. As of September 30, 2023, the company achieved a revenue growth rate of approximately 154.13%. This indicates a substantial increase in the company’s profits. Compared to its peers, revenue growth lags that of industry peers. The company achieved a below-average growth rate among its healthcare peers.
Net margin: Mirum Pharmaceuticals’ net margin exceeds industry standards, highlighting the company’s exceptional financial performance. With an impressive -49.42% net margin, the company effectively manages costs and achieves strong profitability.
Return on equity (ROE): Mirum Pharmaceuticals’ ROE is lower than industry standards, indicating difficulty in efficiently utilizing equity capital. With an ROE of -13.57%, the company may experience difficulty in providing satisfactory returns to shareholders.
Return on Assets (ROA): Mirum Pharmaceuticals’ financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a notable ROA of -4.31%, the company demonstrates efficient use of resources and solid financial health.
Debt Management: With a high debt-to-capital ratio of 1.14Mirum Pharmaceuticals faces challenges in effectively managing its debt levels, indicating potential financial strain.
What are analyst ratings?
Within banking and financial systems, analysts specialize in reporting for specific securities or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish “analyst ratings” for stocks. Analysts typically evaluate and rate each stock once a quarter.
In addition to their standard ratings, some analysts contribute forecasts on metrics such as growth, earnings and revenue estimates, providing investors with additional guidance. Users of analyst ratings should be aware that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.